What outcomes has Cosentyx (secukinumab) shown in plaque psoriasis?
In plaque psoriasis, Cosentyx is used to reduce skin lesions and improve symptoms. Trials and long-term data have reported high rates of skin clearance and symptom improvement, commonly measured as:
- PASI scores (how much psoriasis affects the skin)
- IGA responses (clear/almost clear skin)
- Dermatology Life Quality Index (DLQI) improvements (how much psoriasis affects daily life) [1][2]
What outcomes has Cosentyx shown for psoriatic arthritis?
For psoriatic arthritis, Cosentyx outcomes are typically tracked through improvements in:
- Joint symptoms and inflammation (including swollen/tender joint counts)
- Physical function and activity limitations
- Skin outcomes alongside joint outcomes
- Patient-reported measures such as pain and quality of life
Clinical studies have reported improvements across these domains versus placebo or standard approaches, and sustained responses have been reported with continued treatment [2][3].
What outcomes has Cosentyx shown for ankylosing spondylitis and non-radiographic axial spondyloarthritis?
Cosentyx outcomes in axial spondyloarthritis focus on reducing inflammation and improving function, using measures such as:
- ASAS responses (axial symptom improvement)
- MRI inflammation changes (when assessed)
- Physical function and pain outcomes
Studies have shown improvements in these axial measures compared with placebo, with responses sustained in longer-term follow-up [2][3].
How fast do outcomes typically happen with Cosentyx?
Patients usually look for early skin and symptom changes. Across indications, outcomes often improve over the first several weeks, with many trials showing progressively higher response rates with ongoing dosing through the early and mid-term phases (for example, week-by-week increases in PASI/IGA responses in psoriasis). Exact timelines vary by indication and patient baseline severity [1][2].
What outcomes matter most to patients (skin, joints, and quality of life)?
Across psoriasis and psoriatic arthritis, Cosentyx outcomes that patients commonly value include:
- Clearer skin and fewer plaques
- Less joint pain and stiffness
- Better ability to work, move, and do daily activities
- Better overall quality of life
Those outcomes are captured in study endpoints like PASI/IGA and quality-of-life instruments such as DLQI [1][2].
Are there differences in outcomes by dosing or prior treatments?
Reported outcomes can vary based on factors such as:
- Whether a patient has previous biologic exposure
- Disease severity and baseline symptom burden
- Whether the patient’s main problem is skin, joints, or axial symptoms
Clinical trial programs include subgroup analyses and longer-term extension data, which show that many patients respond, including those who had prior inadequate response to other treatments, though response rates can differ by subgroup [2][3].
What safety outcomes should you consider alongside effectiveness?
“Outcomes” also include tolerability and safety. In practice, patients and clinicians consider risks such as:
- Common infections and how they’re managed
- Monitoring during treatment
Safety findings are reported across clinical trials for each indication and are reflected in prescribing information [1][2].
---
Sources
[1] https://www.cosentyx.com/
[2] https://www.rxlist.com/cosentyx-drug.htm
[3] https://www.ema.europa.eu/en/medicines/human/EPAR-cosentyx